Media headlines about Jaguar Animal Health (NASDAQ:JAGX) have been trending somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research firm rates the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Jaguar Animal Health earned a coverage optimism score of 0.12 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 45.5743765892388 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Here are some of the media headlines that may have effected Accern Sentiment Analysis’s analysis:

Shares of Jaguar Animal Health (NASDAQ:JAGX) opened at 0.5332 on Wednesday. The firm’s market capitalization is $7.70 million. Jaguar Animal Health has a 12-month low of $0.50 and a 12-month high of $1.84. The company has a 50-day moving average price of $0.60 and a 200-day moving average price of $0.78.

A number of research firms recently weighed in on JAGX. HC Wainwright set a $2.00 price objective on Jaguar Animal Health and gave the company a “buy” rating in a report on Tuesday, July 11th. Rodman & Renshaw began coverage on Jaguar Animal Health in a report on Tuesday, July 11th. They issued a “buy” rating and a $2.00 price objective for the company.

ILLEGAL ACTIVITY NOTICE: “Jaguar Animal Health (JAGX) Getting Somewhat Favorable Media Coverage, Study Shows” was reported by Daily Political and is owned by of Daily Political. If you are reading this story on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/08/09/jaguar-animal-health-jagx-getting-somewhat-favorable-media-coverage-study-shows.html.

About Jaguar Animal Health

Jaguar Animal Health, Inc is an animal health company. It is focused on developing and commercializing gastrointestinal products for companion and production animals, foals, and horses. Canalevia is its prescription drug product candidate, intended for treatment of various forms of diarrhea in dogs. Canalevia is a canine-specific formulation of crofelemer, an active pharmaceutical ingredient (API) isolated and purified from the Croton lechleri tree.